ImmunityBio, Inc.

To our Veterans: Thank you for your service. As we honor you today, we recognize the impact of bladder cancer on the Veteran community. According to a new ImmunityBio survey conducted by @HarrisPoll, 53% of Veterans and military service members with NMIBC were diagnosed by age 50, including 28% by age 40. Throughout November, we’ll be sharing what Veterans told us about navigating NMIBC to bring greater awareness to their experiences and needs. Learn more about what Veterans shared: immunitybio.com/new-u-s-surv…

Each November, #LungCancerAwarenessMonth highlights the importance of education, early detection, and innovation. ImmunityBio is proud to support this awareness by researching new approaches for patients with lung cancer, where significant unmet need remains.

ImmunityBio is heading to #LUGPA2026. We look forward to learning, connecting, and celebrating the strength of independent urology with practice leaders and clinicians. Visit us at booth #712 to connect with our team.

ImmunityBio Medical Affairs leadership will be attending #SITC26, taking place November 4-8 in Phoenix. We're excited to connect with colleagues across the oncology community and take part in conversations advancing cancer immunotherapy. If you're attending, we hope to see you there.

We were honored to join the oncology community at #ESMO26 in Madrid, sharing progress in our mission to harness the power of immunotherapy. The energy and collaboration throughout the week reinforced what drives us: advancing innovative treatments with the goal of improving outcomes and quality of life for patients worldwide. Thank you to our team and collaborators who make this work possible.

Progress in research happens one study at a time. We're committed to transparency in our clinical development programs. Stay informed about where our investigational candidates stand. Check our latest pipeline updates: immunitybio.com/pipeline/

ImmunityBio is excited to attend the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid - a highly influential global oncology meeting bringing together clinicians, researchers, patient advocates, and industry leaders from around the world. #ESMO26 will be a platform for advances in oncology research, clinical practice, and patient care. We look forward to engaging with the global oncology community, exploring impactful new data, and contributing to the future of cancer care on a global scale. @myESMO

We're hiring at our new Dunkirk facility. ImmunityBio is expanding our manufacturing operations and seeking talented professionals in Manufacturing & Operations, QA/QC, Process Engineering, and Regulatory Affairs. Join us in our mission to develop innovative immunotherapies that transform patient outcomes. Apply now: immunitybio.com/careers/

According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States. Through clinical research and collaboration, ImmunityBio is researching medications aiming to help those affected. Learn more about our research and clinical trials: immunitybio.com/non-small-ce…

We're excited to join the World Bladder Cancer Patient Forum 2026 in Hong Kong, bringing together voices from across the globe to advance bladder cancer care and advocacy. Today, ImmunityBio's Anjali Malhotra joined a panel on patient-centric clinical trial design, contributing to an important conversation about putting patients at the center of research. #BladderCancerForum26

On World Lymphoma Awareness Day, we stand with the more than 1 million people worldwide living with lymphoma, including those facing Non-Hodgkin's Lymphoma, the most common form of this disease. At ImmunityBio, we are dedicated to advancing innovative immunotherapy approaches that are being studied for patients with Non-Hodgkin's Lymphoma. Today, we honor the patients, caregivers, and healthcare providers confronting lymphoma every day. Your strength drives our science.

ImmunityBio is expanding our team. We're seeking passionate professionals across research, clinical development, manufacturing, and corporate functions who share our commitment to advancing immunotherapy. Explore open roles: immunitybio.com/careers

September is Ovarian Cancer Awareness Month, a time to shine light on a disease that often goes undetected until its later stages. At ImmunityBio, researchers continue working to develop new treatment options for women facing ovarian cancer. Our work is driven by a commitment to develop investigational immunotherapies where options are limited. We honor the strength of patients and families navigating this journey, and we remain dedicated to advancing research that could transform outcomes. Learn more about our research: immunitybio.com/ovarian-canc…

This past Sunday, we proudly participated in @GO2forLungCancr's first Annual 5K in Nashville. We joined patients, caregivers, and advocates with a shared commitment to improve outcomes for those affected by lung cancer. Thank you to everyone who helped make this event a success. Every step helped raise awareness, support the lung cancer community, and reinforce our commitment to advancing treatment options for patients. Together, we're moving the fight against lung cancer forward – one step at a time.

Meaningful conversations about clinical trials and the future of bladder cancer happening at #BCANTT26. ImmunityBio is grateful to stand with @BladderCancerUS in their mission to support patients and caregivers every day. #BladderCancer

At ImmunityBio, we're conducting clinical research to better understand glioblastoma and evaluate investigational therapies that may offer new options for patients facing this difficult diagnosis. Learn more by visiting: immunitybio.com/glioblastoma…

Be part of something bigger. At ImmunityBio, we're developing innovative cancer therapies, and we need dedicated people like you to help us strive to improve patient outcomes. Explore opportunities to join our team: immunitybio.com/careers/